Mizuho analyst Salim Syed raised the firm’s price target on Amgen to $214 from $208 and keeps a Neutral rating on the shares. The analyst updated the firm’s model post the Q1 results.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
- Coherus Biosciences initiated with a Buy at Truist
- Galera Therapeutics expands commercial leadership team
- Amgen price target lowered to $225 from $227 at Barclays
- Amgen price target lowered to $288 from $293 at Piper Sandler
- AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
Questions or Comments about the article? Write to editor@tipranks.com